David Basher serves as the Vice President of US Oncology Commercial at Natera, where he leverages his extensive experience in sales management and commercialization to drive innovative solutions in cancer care. With a robust background spanning 18 years in the molecular diagnostics and biotech sectors,...
David Basher serves as the Vice President of US Oncology Commercial at Natera, where he leverages his extensive experience in sales management and commercialization to drive innovative solutions in cancer care. With a robust background spanning 18 years in the molecular diagnostics and biotech sectors, David has established himself as a transformational leader, adept at navigating both start-up environments and mature markets. His expertise lies in developing and executing “Go-To Market” strategies that enhance patient outcomes through cutting-edge technologies, particularly those harnessing the power of DNA from a single blood sample.
At Natera, David is at the forefront of key projects aimed at revolutionizing cancer management. He leads initiatives that focus on the integration of advanced genomic testing into clinical practice, facilitating better decision-making for oncologists and improving patient care pathways. His leadership has been instrumental in fostering relationships with key opinion leaders (KOLs) and major institutions, ensuring that Natera's innovative products are effectively positioned within the oncology landscape.
David's commitment to excellence is reflected in his recognition as a three-time Leadership Award recipient, underscoring his ability to inspire cross-functional teams and drive sales performance. His skills in training and development have empowered sales teams to excel in a competitive environment, while his strategic insights into marketing and hospital sales have positioned Natera as a leader in the oncology diagnostics space. As he continues to advance Natera's mission, David remains dedicated to improving the lives of cancer patients through innovative, evidence-based solutions.
